A part of Watch Media

Monday20 March 2023

10/06/2022at 15:24

Top news from MedWatch this week

Miss anything?

Photo: MedWatch

by MIKKEL AABENHUS HEMMINGSEN

Tuesday

Ambu recalls single-use product one year after launch

Zealand Pharma obesity drug continues to phase II

Eli Lilly squares up to Novo Nordisk on obesity market

Canada places USD 56m monkeypox vaccine order at Bavarian Nordic

Wednesday

General Manager of Novo Nordisk in Denmark to move to Japan

Bavarian Nordic eyes opportunities in huge pox vaccine stockpiles

Lundbeck shareholders approve new equity structure

Thursday

Influencer collaborations common in hearing aid industry

MC2 Therapeutics chief medical officer to step down, will be replaced by Chief Physician

Professor claims Eli Lilly’s tirzepatide could essentially eradicate type 2 diabetes

Friday

Employee perception of leadership harms image at three prominent life science firms

Genmab launches new case against Janssen, demands compensation and royalties

Bavarian Nordic upgrades guidance for third time in three weeks

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Foto: Gn/pr

William Demant Invest report reveals GN Group stake

The investment firm’s ownership share in GN Group was enough to foil plans to raise DKK 7bn.

For subscribers

Foto: Leo Pharma/pr

Pharma & biotech

Adolescent patients' eczema improved in Leo Pharma's late-stage testing

For subscribers

Foto: Gn/pr

DNB surprised by GN's lack of backup plan

For subscribers

Foto: Leo Pharma/pr

Pharma & biotech

Leo Pharma presents positive data in hand eczema phase III trial

For subscribers

Foto: Guillaume Souvant/Reuters/Ritzau Scanpix

Pharma & biotech

Six-month Ozempic shortage mostly over after weight-loss craze drained supply

For subscribers

Foto: Tingshu Wang/Reuters/Ritzau Scanpix

Competition sharpens on active ingredient production – EU weighs measures

For subscribers

Further reading

Foto: Gn/pr

DNB surprised by GN's lack of backup plan

The lack of support for GN’s scrapped capital raise was to be anticipated, says a DNB analyst, meaning it would have made sense to make a plan B in advance.

For subscribers

Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

Pharma & biotech

Novo Nordisk reacts to suspension: "We take the decision very seriously"

Novo Nordisk, which has been ousted from UK pharma group ABPI for two years, does not want to comment further on its punishment for misleading marketing.

For subscribers

Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

Pharma & biotech

UK pharma group suspends Novo Nordisk for two years

Novo Nordisk has been suspended due to misleading marketing that breached the Code of Practice of the Association of the British Pharmaceutical Industry.

For subscribers

Jobs